SCHEMBL12575121

SCHEMBL12575121

Cc1nnc2c(N(C)Cc3ccccc3)nccn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA1 P14867 1/20 0.47
▸ GABRG2 P18507 1/20 0.47
▸ GABRB3 P28472 1/20 0.47
▸ GABRA5 P31644 1/20 0.47
▸ BRD4 O60885 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ LMNA P02545 4/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ TP53 P04637 2/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ METAP2 P50579 1/20 0.41
▸ METAP1 P53582 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12476483 0.85 GABRA1 (0.43) GABRA1GABRG2GABRB3GABRA5ALDH1A1
SCHEMBL12574994 0.83 BRD4 (0.43) GABRA1GABRG2GABRB3GABRA5BRD4
SCHEMBL12638869 0.81 MAPK14 (0.42) GABRA1GABRG2GABRB3GABRA5BRD4
SCHEMBL12575109 0.80 EGFR (0.38) TSHRMAPK1HSD17B10CYP1A2CYP3A4
SCHEMBL2021495 0.77 ZAP70 (0.40) GABRA1GABRG2GABRB3GABRA5BRD4
SCHEMBL2024425 0.75 GABRA1 (0.44) GABRA1GABRG2GABRB3GABRA5BRD4
SCHEMBL12575068 0.75 FLT1 (0.35) BRD4
SCHEMBL12574657 0.73 GRM5 (0.39) GABRA1GABRG2GABRB3GABRA5BRD4
SCHEMBL12575060 0.73 CYP1A2 (0.46) BRD4ALDH1A1HPGDLMNAKDM4E
SCHEMBL12575075 0.72 ADORA3 (0.55) BRD4ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329705-B2 Substituted triazolo-pyrazine compounds ARQULE, INC. (US) 2012-12-11 — — US disclosed
US-20110160215-A1 Substituted Triazolo-Pyrazine Compounds ARQULE, INC. (US) 2011-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160215-A1 Substituted Triazolo-Pyrazine Compounds MKI67, TP53, THPO GABRA1 3427/4885GABRG2 3483/4885GABRB3 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback